| Literature DB >> 22114779 |
Alberto J Montero1, Betsy Adams, C Marcela Diaz-Montero, Stefan Glück.
Abstract
The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane(®)) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol(®)) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22114779 DOI： 10.1586/ecp.11.7
Source DB: PubMed Journal: Expert Rev Clin Pharmacol ISSN： 1751-2433 Impact factor: 5.045